ProCE Banner Activity

Key Decisions in HIV Care: Choosing ART in the Context of Virologic Failure and Resistance

Podcast Episodes
In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.

Released: December 29, 2021

Expiration: December 28, 2022

No longer available for credit.

Share

Faculty

Josep M. Llibre

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

Josep M. Llibre, MD, PhD, has disclosed that he has served on an advisory board or panel and as a consultant for Gilead Sciences, Janssen, MSD, and ViiV.